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Kbus/Idr, a mutant mouse strain with skeletal
abnormalities and hypophosphatemia:











Background: The endopeptidase encoded by Phex (phosphate-regulating gene with homologies to
endopeptidases linked to the X chromosome) is critical for regulation of bone matrix mineralization and phosphate
homeostasis. PHEX has been identified from analyses of human X-linked hypophosphatemic rickets and Hyp
mutant mouse models. We here demonstrated a newly established dwarfism-like Kbus/Idr mouse line to be a
novel Hyp model.
Methods: Histopathological and X-ray examination with cross experiments were performed to characterize Kbus/
Idr. RT-PCR-based and exon-directed PCR screening performed to identify the presence of genetic alteration.
Biochemical assays were also performed to evaluate activity of alkaline phosphatase.
Results: Kbus/Idr, characterized by bone mineralization defects, was found to be inherited in an X chromosome-
linked dominant manner. RT-PCR experiments showed that a novel mutation spanning exon 16 and 18 causing
hypophosphatemic rickets. Alkaline phosphatase activity, as an osteoblast marker, demonstrated raised levels in the
bone marrow of Kbus/Idr independent of the age.
Conclusions: Kbus mice should serve as a useful research tool exploring molecular mechanisms underlying
aberrant Phex-associated pathophysiological phenomena.
Keywords: Bone defects, Hypophosphatemia, Mouse model, Phex, Hyp, XLH
Background
During the maintenance of the KYF/MsIdr strain of
mouse, which earlier spontaneously yielded an abnormal
behavior-displaying Usher-1D model, BUS/Idr [1,2], we
recognized the occurrence of dwarfism-like short-tailed
individuals, which displayed distinct bustling behavior.
We have established the mutant as a new strain, Kbus/
Idr, through brother-sister mating, and attempted to
specify the responsible gene(s), as dealt with in this
paper.
Introduction
Osteogenesis is controlled by osteoblast/osteoclast func-
tional balance in close association with phosphate (Pi)
homeostasis regulated by complicated systems operating
across the parathyroid gland, intestine, bone and kidney
[3,4]. Parathyroid hormone (PTH), 1,25-vitamin D3 and
calcium-sensing receptors constitute the classic pathway
of Pi/calcium homeostasis, which is essential for bone
differentiation and remodeling. In addition, two impor-
tant key mediators have been identified through clinical
observation and subsequent molecular approaches,
fibroblast growth factor-23 (FGF23) and a phosphate-
regulating gene product with homology to endopepti-
dases linked to the X chromosome (PHEX). Gain-of-
function mutations of FGF23 lead to autosomal domi-
nant hypophosphatemia/osteomalacia [5], while its loss-
of-function mutations are causative of recessive familial
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secreted mainly from osteoblasts/osteocytes [8,9], is a
potent inhibitor of renal Pi reabsorption, leading to
phosphate wasting. This phosphaturic hormone binds to
renal FGF23 receptor (FGF23r)/Klotho heterodimeric
molecules much more tightly than to FGF23r alone,
thereby exerting marked inhibitory actions against renal
Pi reabsorption [10,11].
PHEX, another potent mediator of phosphate homeos-
tasis, has been identified from analyses of human X-
linked hypophosphatemic rickets (XLH) [12] and Hyp
mutant models [13,14]. Loss-of-function mutations of
PHEX/Phex lead to skeletal abnormalities and hypopho-
sphatemia, and are genetically fully dominant [15].
Aberrant PHEX/Phex expression also results in abnorm-
alities in cartilages [16,17] and teeth [18]. Phex belongs
to the M13-type plasma membrane-integrated metal-
loendopeptidase family, and is expressed exclusively in
cells of the osteoblast/osteocyte lineage [19,20]. Accu-
mulating evidence indicates that the Phex substrates are
protease-resistant acidic serine-aspartate-rich motif pep-
tides (ASARM peptides) generated from small integrin-
binding ligand, N-linked glycoproteins (SIBLING pro-
teins) by cathepsin actions [21-29]. Phex interacts with
and degrades ASARM peptides of SIBLINGs, such as
matrix extracellular phosphoglycoprotein (MEPE), osteo-
pontin and dentin matrix protein 1. Although the SIB-
LINGs are not highly homologous in structure [30],
their ASARM peptides bind, in a phosphorylation-
dependent manner, to matrix Ca × PO4 to inhibit
mineralization. Both SIBLINGs and ASARM peptides
are increased in Hyp and human XLH and strongly
inhibit renal Pi reabsorption [23,31]. Finally, transgenic
mice overexpressing MEPE in bone mimic the Hyp
model, displaying growth and mineralization defects
with altered bone-renal vascularization [32].
To date, six Phex mutant models, Hyp (a 3’-deletion
of the Phex gene) [13,14], Gy (partial deletion of both
spermine synthase and Phex) [13,33], Phex(Ska1) (skip-
ping of exon 8) [34], Hyp-J2 (deletion of exon 15) [35],
Hyp-Duk (deletion of exons 13 and 14) [35], and Phex
(pug) (glycosylation defects due to Phe-to-Ser substitu-
tion at a.a. 80 of Phex) [36] have been reported, while
over 260 human disease-associated PHEX mutations
have been identified [37-41]http://http:/www.phexdb.
mcgill.ca. We have now established a dwarfism-like
strain of short-tailed mouse, Kbus/Idr, carrying a novel
intragenic deletion of the Phex gene.
Materials and methods
Mice
Highly inbred Kbus/Idr mice, maintained for over 20
generations were used. Kbus mice were of KYF/MsIdr-
origin, and hence KYF mice were used as control
animals. All were housed in an air-conditioned room in
the Institute for Developmental Research, Aichi Human
Service Center, Kasugai, Japan, with a constant tempera-
ture (23 ± 1°C) and humidity (55 ± 10%) on a 12:12-hr
light-dark cycle with lights on at 7:00 a.m., with free
access to standard laboratory diet (CE-2; CLEA Japan
Inc.). The animals were handled in accordance with the
institute guidelines. Frozen Kbus embryos are now avail-
able from RIKEN BioResource Center, Tsukuba, Japan.
Histopathology and X-ray examination
The detailed methods for histopathological examination
are described in the legends of Additional file 1, Figure
S1 and Additional file 2, Figure S2. To evaluate bone
density, age-matched Kbus and KYF mice were sub-
jected to X-ray irradiation at 40 kV and 100 mA for 6
seconds, together with eleven ceramid strips with gra-
dual X-ray transmissivity rates (X-TR), 1 to 11, where
X-TR 11 represented the highest TR.
Biochemical experiments
Blood was collected from deeply anesthetized mice, 8
weeks of age, and mixed with an equal volume of 10%
trichloroacetic acid and centrifuged at 12,000 × g for 10
min. The supernatants obtained were directly subjected
to Pi assay, according to the method of Fiske and Sub-
baRow [42]. Bone marrow stromal cells (BMSCs) were
obtained from the femurs, washed once with phosphate-
buffered saline (PBS) and sonicated in 50 mM Tris-1
mM EDTA, pH 6.8, containing 0.1% Triton X-100.
Alkaline phosphatase (ALP: osteoblast marker) and tar-
trate-resistant acid phosphatase (TRAP: osteoclast mar-
ker) were assayed at 37°C in 0.1 M glycine-NaOH, pH
10.0, and 0.1 M acetate buffer containing 0.3 M sodium
tartrate, pH 4.2, respectively, using 2 mM nitrophenyl-
phosphate (NPP) as the substrate. One unit of enzyme
was defined as that releasing 1 μmole of Pi from NPP
per min. Protein was measured with a BCA Protein
Assay Reagent Kit (Pierce). Serum ALP levels were
assessed as described above with x2 diluted serum sam-
ples from 14-week-old males. The results were pre-
sented as the means ± SEM, and statistically analyzed by
Student’s t-test, where differences of P <0 . 0 5w e r ec o n -
sidered significant.
Cross experiments and PCR analysis
The phenotype of all progeny was judged at 8-weeks of
age, based on the tail length and dwarfism-like appear-
ance, as well as bustling behavior. The results of Kbus-
KYF crosses gave simple segregation patterns in these
traits, as shown in the Results section.
For RT-PCR-based screening for mutations of mouse
Phex, total RNA fractions were prepared from bony tis-
sues of 3 to 12-day-old mice (Total RNA purification
Moriyama et al. Journal of Biomedical Science 2011, 18:60
http://www.jbiomedsci.com/content/18/1/60
Page 2 of 8kit; Stratagene). Oligo dT-primed and Phex-specific
reverse R6 (Additional file 3, Table S1)-primed first
strand cDNAs were prepared using Superscript III (Stra-
tagene), and PCR was carried out with AmpliTaq-Gold
(Roche-Applied Biosystems). DNAs were prepared by
digestion of homogenized fresh livers with proteinase K
in the presence of pancreatic RNase, EDTA and SDS,
followed by extraction with phenol. The primer sets
used for RT-PCR-based and exon-directed PCR-based
screening are shown in Additional file 3, Table S1. The
nucleotide sequences of all PCR products were verified
with an ABI PRISM 310 genetic analyzer (Applied
Biosystems).
Results
Characterization of Kbus/Idr mice
Kbus mice were distinguishable from KYF mice because
of a growth defect resulting in a dwarfism-like appear-
ance and short tail (Additional file 1, Figure S1). They
exhibited bustling behavior, but swam well, indicating
vestibular function to be normal. Kbus mice also exhib-
ited normal startle responses to sounds (popping with
hands), indicating that they heard. Since no degenerative
features of Corti’s organ or spiral ganglion cells were
observed in Kbus inner ears (not shown), we concluded
that they had no serious inner ear defects. We further
noted that the bustling behavior in Kbus was absolutely
linked to bone defects in Kbus-KYF crosses, but was
almost nullified in F2 progeny of Kbus-C57BL/6 crosses,
suggesting the behavioral abnormality to be dependent
on the KYF background. Therefore, our primary atten-
tion in this study was focused on skeletal abnormalities
in Kbus mice.
Defective features in Kbus bones were apparent in
cleared whole body skeletal preparations (Additional file
2, Figure S2) and histopathological examination (Addi-
tional file 4, Figure S3): Each of the long bones and
bony segments of the tail was shorter than the couter-
part in KYF mice, resulting in a shorter tail and dwarf-
ism-like features of Kbus mice. In Kbus cortical bones
many sinuses were observed even at 12 weeks of age;
consequently, the long bones of Kbus adults had a
deranged Haversian system and branched marrows, indi-
cating defective vascularization and incomplete differen-
tiation of dense cortical bone. In Kbus cartilage,
abnormally thick toluidine blue-positive growth plates
were evident. Finally, the X-ray examinations revealed
reduced bone density (Figure 1), X-TR values for the
cortical bone of the central tibia being 8~10 for Kbus
and X-TR 4~5 for KYF.
Identification of Kbus mice linkage to a Hyp allele
In crosses between Kbus females and KYF males, all F1
progeny exhibited skeletal abnormalities, while only F1
females were affected in crosses of KYF females and
Kbus males (Table 1). This, together with the backcross
data, was consistent with the view that the Kbus pheno-
type was controlled by a dominant gene linked to the X
chromosome. Phenotypic segregation in F2 males, but
not females, was different from the theoretical values
(double asterisks in Table 1), due most probably to the
small number of F2 progeny.
Given that Kbus mice displayed a bone matrix minera-
lization defect inherited in an X chromosome-linked
dominant manner, we considered that the mutant might
carry a Hyp allele. Indeed, blood Pi levels in Kbus were
significantly low, and hypophosphatemic traits were also
dominant (Additional file 3, Table S2 and right panel of
Figure 2). In addition, serum ALP levels in Kbus were
significantly higher than those of KYF values (48.5 ± 4.1
munits/ml of serum vs. 18.4 ± 2.7 munits/ml of serum,
p < 0.01, n = 5; left panel of Figure 2), consistent with
t h ed a t af o rH y pa n dX L H[ 3 ] .W et h e r e f o r ea t t e m p t e d
to detect mutations of the Phex gene. In RT-PCR
experiments, we could obtain no PCR products for an
exons 16-18-associated region (Figure 3). We emphasize
here that we applied different sets of primers (not listed
in Additional file 3, Table S1) to detect the region, and
n os e tg a v ep o s i t i v er e s u l t s ,e v e nw h e ns p e c i f i cR 6 -
primed first strand cDNAs were employed as templates
(Figure 3). Although F6/R6-PCR products were regularly
fewer in Kbus than in KYF in repeated experiments, the
nucleotide sequences could be verified as essentially the
same. Finally, no PCR products for exons 16, 17 and 18
were detected in the Kbus genome, indicating an intra-
genic deletion spanning 10-40 kb (Figure 4). Again, the
PCR products for exon 19 were regularly fewer in Kbus
than in KYF, but without nucleotide changes.
High alkaline phosphatase activity in isolated Kbus
BMSCs
In view of the aberrant Phex-induced reduction in skele-
togenesis, the mutant elevated serum ALP activity
appeared of interest, given that ALP was an osteoblast
marker, and because Hyp BMSCs indicated reduced
osteoblastogenesis and skeletogenesis in culture [24-26].
Examination of ALP and TRAP levels in total BMSCs
demonstrated raised levels of only the former in Kbus as
compared to KYF BMSCs independent of the age (Table
2). ALP-positive cells in the bone marrow could thus
have been the source of high serum ALP.
Discussion
The present study demonstrated the Kbus strain, here
referred to as Hyp(Kbus), to carry a novel genetic altera-
tion of the Phex gene. It was suspected that the distinct
bustling behavior and skeletal abnormalities might be
controlled by a single gene. Abnormal behavior, such as
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Page 3 of 8Figure 1 X-ray examination for assessing skeletal deformation and mineralization defects in Kbus mice. X-rays were applied at 40 kV and
100 mA for 6 seconds to Kbus and KYF adult (panel 1) femurs (panels 2 and 3) and humeri (panel 4). A set of eleven hydroxyapatite plates with
different X-ray transmissivity rates (X-TR), X-TR1 to 11, where 1 had the least X-TR, was used to assess bone mineralization. The hydroxyapatite
plates (HP in panel 1) are seen in each panel (on the top in panels 2-4). For the cortical region of the central part of the tibia, X-TR values of
8~10 and 4~5 were obtained for Kbus and KYF, respectively.
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inner ear defects in mice [1,2]; and two Hyp models, Gy
and Hyp-Duk [34,36], have also been reported to display
abnormal behavior. However, deafness and endolympha-
t i ch y d r o p sd u et ot h ePhex
Hyp-Duk mutation exhibit
background-dependent variable expression [35,43]; and
in the Gy, alteration of the spermine synthase gene,
rather than Phex, is responsible for inner ear defects
[44]. We should stress here that the inner ears of Hyp
(Kbus) have normal histological features, and their char-
acteristic bustling behavior is relatively slight compared
with that of inner ear defect-bearing BUS mice [1].
Furthermore, the behavioral trait was almost nullified in
F2 progeny in outcrosses with C57BL/6 mice, suggesting
the Hyp(Kbus) behavior to be background-dependent.
No clear association between defective PHEX and inner
ear defects has been specified in humans, while some
XLH patients have hearing impairment [45].
Hyp models have greatly contributed to our under-
standing of bone matrix mineralization and maintenance
of the Pi balance. Aberration of the Phex-SIBLINGs sys-
tem leads to remarkable elevation in FGF23 [46-49], and
it is now evident that increased levels of FGF23,
ASARM and MEPE account for various pathophysiologi-
cal phenomena described earlier in XLH and Hyp ani-
mals. However, the implications and mechanisms of
Hyp-induced elevation of FGF23 have remained unclear,
because the main sites of FGF23 production are osteo-
blasts/osteocytes [8,9], and because Phex deficiency
should result in diminished osteogenesis. Equally
unclear have been the source and implications of
increased serum ALP activity in Phex deficiency. In gen-
eral, serum ALP activity and the number of ALP-posi-
tive osteoprogenitor cells in BMSC culture correlate
with bone-forming ability and bone density [50]. In Hyp
models, however, this is not the case, because cultured
Table 1 Phenotype segregation in cross experiments




F2 progeny of F1(ab
1) × F1(ab) Backcross of F1(ab) × KYF
normal abnormal normal abnormal
female 0 7 6 6
male 2** 9** 6 9




F2 progeny of F1(ab) × F1(n
1) Backcross of F1(ab) × Kbus
normal abnormal normal abnormal
female 4 4 0 6
male 3** 12** 6 7
1 ab and n, abnormal and normal in phenotype, respectively.
* Individuals displaying both short tail (body > tail in length) and bustling
behavior were taken as abnormal.
** Significantly different from the theoretical values, assuming that the traits
are inherited in an X-linked dominant manner.
Figure 2 Blood phosphorus levels in 8-week-old KYF and Kbus mice, showing Kbus mice to be hypophosphatemic (right panel).N o
significant variation was observed between homozygous and heterozygous Kbus females, indicating the hypophosphatemic character to be fully
dominant. n = 3. Also refer to Additional file 3, Table S2. Serum ALP levels in 14-week-old KYF and Kbus mice, showing extremely high activities
in Kbus (left panel). n = 5. Asterisks indicate the statistical significant difference for the values of age-matched KYF samples (p < 0.01).
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letogenesis [24-26]. Based on the present finding that
isolated Hyp(Kbus) BMSCs exhibit significantly elevated
ALP activity, we suggest that ALP-containing osteoblast-
like cells in the bone marrow are the source of ALP
increase in serum, further indicating that most of these
ALP-positive BMSCs could be non-adherent or unable
to survive in culture. It is necessary to specify the role
and the fate of ALP-positive cells abundant in Hyp
(Kbus) bone marrow.
Hyp models have another important contribution as
research tools for therapeutic approaches. It appears
that rescue of the Hyp phenotype can be accomplished
by expression of the PHEX transgene over a long period
of time under control of a bone-specific promoter [51],
although in some reports there was only partial rescue
by the transgene of Hyp abnormalities [52-54]. Recently,
it has been noted that Hyp/klotho-/- knockout mice
lack the hypophosphatemia and mineralization defects
of Hyp, but with a shortened life span [55,56]. Hyp
m o d e l sc a nb ee x p e c t e dt op l a yap a r ti np r o v i d i n g
further clues to therapeutic manipulation of Pi balance-
associated disorders.
Conclusions
Histopathological and molecular genetic analyses here
demonstrated a newly established dwarfism-like Kbus/
Figure 3 RT-PCR screening of the Phex transcripts in Kbus bony tissues. The primer sets used are shown in Additional file 3, Table S1.
Oligo-dT-primed (left panel) and Phex-specific R6-primed (right panel) first strand cDNAs were prepared from Kbus (KB) and KYF (K) bony tissues.
No PCR products were obtained for exon 16-18-associated regions, even with R6-primed cDNAs used as templates. The regions covered by
different forward (F)/reverse (R) primers are indicated at the bottom. For further details, see the text.
Figure 4 Exon-directed PCR screening of the Kbus Phex gene.
The primer sets used are shown in Additional file 3, Table S1. With
Kbus DNA, no PCR products were obtained with exons 16, 17 and
18, indicating an intragenic 10-40 kb deletion, as depicted at the
bottom. For further details, see the text.
Table 2 Alkaline phosphatase (AP) and tartrate-resistant
acid phosphatase (TRAP) activities in isolated KYF and
Kbus BMSCs
AP activity TRAP activity
4 wks KYF (n = 6) 19.7 ± 1.8 61.2 ± 1.8
Kbus (n = 6) 41.7 ± 4.1* 69.4 ± 4.0
8 wks KYF (n = 7) 16.9 ± 1.9 58.6 ± 2.2
Kbus (n = 8) 20.6 ± 3.7 52.8 ± 3.4
16 wks KYF (n = 8) 8.7 ± 0.7 46.9 ± 2.0
Kbus (n = 8) 18.7 ± 2.9* 43.5 ± 2.3
32 wks KYF (n = 6) 7.3 ± 0.3 43.0 ± 3.2
Kbus (n = 6) 14.1 ± 2.7* 45.4 ± 3.6
munits/mg of protein (mean ± SEM)
Since no significant differences were found between male and female
samples, data from both sexes were combined.
*, Significantly different from the values of age-matched KYF samples (P <
0.05).
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could be important as a tool in further dissection and
understanding of regulatory mechanisms of bone miner-
alization and Pi homeostasis, and in assessment of ther-
apeutic aspects of human bone/Pi-associated disorders.
Additional material
Additional file 1: Figure S1. Comparisons of whole body skeletal
preparations of KYF and Kbus mice. The arizarin Red S/alcian blue
staining method [42] was applied. Each bone of Kbus mice (right
specimen in each panel) is shorter than the counterpart of KYF (left
specimen), which is apparent in the long bones and bony segments of
the tails. The skeletal abnormalities result in a shorter tail and dwarfism-
like looks of Kbus mice. 1, 0-day-old. 2, 5-day-old. 3, 20-day-old. 4, 4-
week-old.
Additional file 2: Figure S2. Histological examinations with Kbus
and KYF femurs. Femur bones from Kbus and KYF mice, 3-week-old (3
wks) and 8-week-old (8 wks), were fixed in Bouin’s solution and
decalcified with neutral 10% EDTA. 8-10 μm paraffin sections were cut,
followed by Masson’s trichrome stain (MT) or toluidine blue stain (TB).
Note many sinuses existing in the cortical bones of Kbus adults,
indicating a deranged Haversian system. The existence of thick growth
plates in Kbus cartilages is also evident, which is one of the characteristic
features of cartilage abnormalities.
Additional file 3: Table S1. Primer sets used for identifying the Phex
transcripts and Phex exons 15-20. Table S2. Blood phosphorus
levels of KYF and Kbus mice.
Additional file 4: Figure S3. Dwarfism-like Kbus mice, originated
from a breeding stock of KYF/MsIdr mice, are smaller than KYF
mice at any age. Each bar represents the mean of body weight values
of at least 20 individuals. Compare the red bars (Kbus female) with the
brown ones (KYF female), and the blue bars (Kbus male) with the grey
ones (KYF male).
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